[ad_1]
the Washington Post On Tuesday raised some provocative questions about Pfizer's R & D activities, by publishing an article highlighting their analysis of an internal group that has demonstrated that their star drug Enbrel could be effective in treating the disease. Alzheimer's – the ultimate holy grail in an industry producing billions on drug programs looking for something that could be used to fight the disease.
It is the story of a big and bad company and its leaders who had their own selfish reasons not to pursue the research themselves. This drug is no longer patent, according to some anonymous critics, and why would Pfizer want to spend the money needed to test the theory that an anti-inflammatory drug could reduce the risk of Alzheimer's disease if it could not? To take advantage of?
Basic subscription required
Instantly discover this story and join more than 52,200 biopharmaceutical professionals who read endpoints daily – for free.
[ad_2]
Source link